At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 334 enrolled
Drug / intervention
Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double Blind Evaluation of Gamma-aminobutyric Acid Tartarate 100 mg, Glutamic Acid 100 mg, Dibasic Calcium Phosphate 50 mg, Thiamine Nitrate 25 mg, Pyridoxine Chloride 10 mg and Cyanocobalamin 5 mcg Versus Ginger for Vertigo-kinetosis
In Brief
A Phase 4 clinical trial evaluating Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin and Ginger for Vertigo. Completed, enrolled 334 participants across 1 site.
Detailed Summary
The goal of this clinical trial is to assess the efficacy and safety of a combination of aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine and cyanocobalamin as adjuvant therapy for vertigo comparatively to ginger under a double-blind randomized study design.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVertigo
CountriesBrazil
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedFeb 2022
Primary CompletionMar 2023
TodayJul 2026
First PostedFeb 3, 2022
Enrollment StartNov 22, 2021
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.4 years ago
Interventions
Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamindrug
Tablets to be taken 30 minutes before each of 4 trips.
Gingerdrug
Tablets to be taken 30 minutes before each of 4 trips.